CytomX director granted 59,000 stock options

CytomX Therapeutics, Inc. director James R. Meyers received a grant of stock options covering 59,000 shares of common stock.

Rhea-AI Filing Summary

CytomX Therapeutics, Inc. director James R. Meyers received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.

According to the award terms, 100% of the options will vest on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds 59,000 derivative securities directly, reflecting a compensation-related award rather than an open‑market purchase.

Insider Trade Summary

Grant/Award: 59,000 shares

Grant/Award 1 txn

Insider Meyers James R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	59,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 59,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Key Figures

Option grant size: 59,000 options Exercise price: $2.96 per share Underlying shares: 59,000 shares +3 more

6 metrics

Option grant size 59,000 options Stock Option (Right to Buy) granted to director

Exercise price $2.96 per share Conversion or exercise price of options

Underlying shares 59,000 shares Common stock underlying the options

Post-transaction holdings 59,000 derivative securities Total options held following transaction

Option expiration June 16, 2036 Expiration date of stock options

Vesting condition 100% by first anniversary or 2027 meeting Requires continuous director service until vesting date

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, Annual Meeting of the Issuer's stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 2.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-16T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Annual Meeting of the Issuer's stockholders financial

"earlier of the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CytomX (CTMX) director James R. Meyers receive in this Form 4?

Director James R. Meyers received a grant of stock options for 59,000 shares of CytomX common stock. These options are a compensation-related award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.

What is the exercise price of the new CytomX (CTMX) stock options?

The stock options granted to James R. Meyers have an exercise price of $2.96 per share. This means he can buy CytomX common stock at $2.96 once the options vest and before they expire, regardless of the market price at that time.

When do James R. Meyers’ CytomX (CTMX) options vest?

All 59,000 options vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of CytomX stockholders. Vesting requires continuous service as a director through that vesting date under the award’s terms.

When do the CytomX (CTMX) stock options granted to James R. Meyers expire?

The granted stock options expire on June 16, 2036. After that expiration date, James R. Meyers can no longer exercise these options to purchase CytomX common shares, even if they are fully vested and otherwise exercisable before then.

Is this CytomX (CTMX) Form 4 an open-market stock purchase or a compensation grant?

This Form 4 reflects a compensation grant, not an open‑market purchase. The transaction code is “A,” described as a grant, award, or other acquisition of derivative securities, with 59,000 stock options awarded at a $2.96 exercise price.

How many CytomX (CTMX) derivative securities does James R. Meyers hold after this grant?

After the reported transaction, James R. Meyers holds 59,000 derivative securities related to CytomX common stock. These represent the full amount of stock options granted in this filing, held directly, subject to the vesting and expiration terms disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meyers James R

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/17/2026		A		59,000		(1)	06/16/2036	Common Stock	59,000	$0	59,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Christopher Ogden, as Attorney-in-Fact for James R. Meyers	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)